Carregant...
Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring
BACKGROUND: Despite a lack of clinical evidence, hydroxychloroquine and azithromycin are being administered widely to patients with verified or suspected coronavirus disease 2019 (COVID‐19). Both drugs may increase risk of lethal arrhythmias associated with QT interval prolongation. METHODS AND RESU...
Guardat en:
| Publicat a: | J Am Heart Assoc |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7429030/ https://ncbi.nlm.nih.gov/pubmed/32463348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.120.017144 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|